GSK's $10.6 billion acquisition of US biotech Nuvalent brings two late-stage lung cancer drugs, neladalkib and zidesamtinib, expected to face regulatory decisions soon. Analysts broadly agree the deal is strategically sound, helping GSK build its oncology portfolio to offset revenue losses from HIV patent expiries between 2028 and 2031. While some see the price as reasonable rather than cheap, the acquisition is viewed as accelerating GSK's oncology growth with relatively low risk. The key trial results for full validation are still years away, but the deal has been met with mostly positive analyst ratings and price targets.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
